Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis

Carcinogenesis

Volumn 35, Issue 5, 2014, Pages 967-973

  Nagaraju, Ganji Purnachandra ^b   Dontula, Ranadheer ^a   El rayes, Bassel F ^b   Lakka, Sajani S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN; MATRIX METALLOPROTEINASE; OSTEONECTIN; SERINE PROTEINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL DIVISION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LUNG CANCER; MEDULLOBLASTOMA; MELANOMA; MOLECULAR BIOLOGY; NEUROBLASTOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER; STROMA CELL; UTERINE CERVIX CANCER;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL ADHESION; CELL MOVEMENT; CELL SURVIVAL; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HUMANS; NEOPLASMS; OSTEONECTIN;

EID: 84901974550     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu072     Document Type: Review

References (127)

1. Bornstein, P. (2002) Cell-matrix interactions: the view from the outside. Methods Cell Biol., 69, 7-11.
2. Brekken, R.A. et al. (2001) SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol., 19, 816-827.
3. Bornstein, P. et al. (2002) Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol., 14, 608-616.
4. Hohenester, E. et al. (1996) Structure of a novel extracellular Ca(2+)-binding module in BM-40. Nat. Struct. Biol., 3, 67-73.
5. Lane, T.F. et al. (1990) Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape. J. Cell Biol., 111(6 Pt 2), 3065-3076.
6. Rahman, M. et al. (2011) A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS One, 6, e26390.
7. Funk, S.E. et al. (1991) The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl Acad. Sci. USA, 88, 2648-2652.
8. Chlenski, A. et al. (2004) Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Res., 64, 7420-7425.
9. Maurer, P. et al. (1996) Extracellular calcium-binding proteins. Curr. Opin. Cell Biol., 8, 609-617.
10. Bradshaw, A.D. et al. (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest., 107, 1049-1054.
11. Brown, P. et al. (1999) Exploring the new world of the genome with DNA microarrays. Exp. Med., 17, 796-803.
12. Koukourakis, M.I. et al. (2003) Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res., 63, 5376-5380.
13. Sato, N. et al. (2003) SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene, 22, 5021-5030.
14. Ledda, M.F. et al. (1997) Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med., 3, 171-176.
15. Schultz, J.E.J. et al. (2002) TGF-ß1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J. Clin. Invest., 109, 787-796.
16. Gilles, C. et al. (1998) SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res., 58, 5529-5536.
17. Nagaraju, G.P. et al. (2013) Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett., 341, 195-203.
18. Rempel, S.A. et al. (1998) SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J. Neuropathol. Exp. Neurol., 57, 1112-1121.
19. Sato, N. et al. (2003) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res., 63, 3735-3742.
20. Tai, I.T. et al. (2005) Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest., 115, 1492-1502.
21. Yiu, G.K. et al. (2001) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol., 159, 609-622.
22. Nagaraju, G.P. et al. (2013) SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. Cancer Lett., 328, 10-17.
23. Bhoopathi, P. et al. (2010) Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ., 17, 1529-1539.
24. Chetty, C. et al. (2012) Blockade of SOX4 mediated DNA repair by SPARC enhances radioresponse in medulloblastoma. Cancer Lett., 323, 188-198.
25. Chetty, C. et al. (2012) SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells. Biochem. Biophys. Res. Commun., 417, 874-879.
26. Yunker, C.K. et al. (2008) SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int. J. Cancer, 122, 2735-2743.
27. Motamed, K. (1999) SPARC (osteonectin/BM-40). Int. J. Biochem. Cell Biol., 31, 1363-1366.
28. Mok, S.C. et al. (1996) SPARC, an extracellular matrix protein with tumorsuppressing activity in human ovarian epithelial cells. Oncogene, 12, 1895-1901.
29. Said, N. et al. (2005) Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am. J. Pathol., 167, 1739-1752.
30. Shin, M. et al. (2013) Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin ß1. The Prostate, 73, 1159-1170.
31. Wong, S.Y. et al. (2008) Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin. Exp. Metastasis, 25, 109-118.
32. Wang, Y. et al. (2005) Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia, 7, 748-760.
33. Brekken, R.A. et al. (2003) Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J. Clin. Invest., 111, 487-495.
34. Chlenski, A. et al. (2002) SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res., 62, 7357-7363.
35. Gorantla, B. et al. (2013) Notch signaling regulates tumor-induced angiogenesis in SPARC-overexpressed neuroblastoma. Angiogenesis, 16, 85-100.
36. Huang, D.Y. et al. (2008) Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J. Pathol., 214, 445-455.
37. Suzuki, M. et al. (2005) Aberrant methylation of SPARC in human lung cancers. Br. J. Cancer, 92, 942-948.
38. Lakhani, S.R. et al.; Breast Cancer Linkage Consortium. (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res., 11, 5175-5180.
39. Dhanesuan, N. et al. (2002) Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res. Treat., 75, 73-85.
40. Koblinski, J.E. et al. (2005) Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res., 65, 7370-7377.
41. Briggs, J. et al. (2002) Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene, 21, 7077-7091.
42. Lien, H.C. et al. (2007) Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene, 26, 7859-7871.
43. Jones, C. et al. (2004) Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res., 64, 3037-3045.
44. Said, N. et al. (2013) Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J. Clin. Invest., 123, 751-766.
45. Gerson, K.D. et al. (2012) Integrin ß4 regulates SPARC protein to promote invasion. J. Biol. Chem., 287, 9835-9844.
46. Fenouille, N. et al. (2011) SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene, 30, 4887-4900.
47. Prada, F. et al. (2007) SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J. Invest. Dermatol., 127, 2618-2628.
48. Arnold, S. et al. (2008) Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp. Biol. Med. (Maywood)., 233, 860-873.
49. Puolakkainen, P.A. et al. (2004) Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res., 2, 215-224.
50. DiMartino, J.F. et al. (2006) Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia, 20, 426-432.
51. Cheetham, S. et al. (2008) SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br. J. Cancer, 98, 1810-1819.
52. Yang, E. et al. (2007) Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int. J. Cancer, 121, 567-575.
53. Chan, S.K. et al. (2008) Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol. Biomarkers Prev., 17, 543-552.
54. Weaver, A.M. (2006) Invadopodia: specialized cell structures for cancer invasion. Clin. Exp. Metastasis, 23, 97-105.
55. Motamed, K. et al. (1998) SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J. Cell. Biochem., 70, 543-552.
56. Rempel, S.A. et al. (2001) SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J. Neurooncol., 53, 149-160.
57. Vadlamuri, S.V. et al. (2003) SPARC affects glioma cell growth differently when grown on brain ECM proteins in vitro under standard versus reducedserum stress conditions. Neuro. Oncol., 5, 244-254.
58. Liu, H. et al. (2011) Knockdown of secreted protein acidic and rich in cysteine (SPARC) expression diminishes radiosensitivity of glioma cells. Cancer Biother. Radiopharm., 26, 705-715.
59. Shi, Q. et al. (2004) Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J. Biol. Chem., 279, 52200-52209.
60. Schultz, C. et al. (2002) Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res., 62, 6270-6277.
61. Bhoopathi, P. et al. (2011) SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42. Cell. Signal., 23, 1978-1987.
62. Huang, S. et al. (2000) Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res., 60, 5334-5339.
63. Haber, C.L. et al. (2008) SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated. Int. J. Cancer, 122, 1465-1475.
64. Huang, H. et al. (2000) Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res., 60, 6868-6874.
65. Chen, J. et al. (2012) SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One, 7, e42413.
66. Yin, J. et al. (2010) Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival. J. Exp. Clin. Cancer Res., 29, 59.
67. Bornstein, P. (2009) Matricellular proteins: an overview. J. Cell Commun. Signal., 3, 163-165.
68. Murphy-Ullrich, J.E. et al. (1995) SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca2+-binding EF-hand. J. Cell. Biochem., 57, 341-350.
69. Sage, E.H. (1992) Secretion of SPARC by endothelial cells transformed by polyoma middle T oncogene inhibits the growth of normal endothelial cells in vitro. Biochem. Cell Biol., 70, 579-592.
70. Sage, H. et al. (1989) SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J. Cell Biol., 109, 341-356.
71. Arnold, S.A. et al. (2012) Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFß activation. PLoS One, 7, e31384.
72. Chew, A. et al. (2011) SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer. PLoS One, 6, e22047.
73. Wang, H.Y. et al. (2012) Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis. J. Transl. Med., 10, 27.
74. Giudici, C. et al. (2008) Mapping of SPARC/BM-40/osteonectin-binding sites on fibrillar collagens. J. Biol. Chem., 283, 19551-19560.
75. Barker, T.H. et al. (2005) SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J. Biol. Chem., 280, 36483-36493.
76. Bradshaw, A.D. (2009) The role of SPARC in extracellular matrix assembly. J. Cell Commun. Signal., 3, 239-246.
77. Nie, J. et al. (2009) SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. J. Biol. Chem., 284, 1279-1290.
78. Kuhn, C. et al. (1995) Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am. J. Pathol., 147, 1759-1769.
79. Chang, W. et al. (2010) SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of betacatenin. J. Biol. Chem., 285, 8196-8206.
80. Bradshaw, A.D. et al. (2003) SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J. Invest. Dermatol., 120, 949-955.
81. Yan, Q. et al. (2002) Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. J. Cell Sci., 115(Pt 13), 2747-2756.
82. Bradshaw, A.D. et al. (2002) SPARC-null mice exhibit accelerated cutaneous wound closure. J. Histochem. Cytochem., 50, 1-10.
83. Bradshaw, A.D. et al. (2001) Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. Wound Repair Regen., 9, 522-530.
84. Meredith, J.E. Jr et al. (1997) Integrins, adhesion and apoptosis. Trends Cell Biol., 7, 146-150.
85. Khwaja, A. et al. (1997) Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J., 16, 2783-2793.
86. Frisch, S.M. et al. (1997) Integrins and anoikis. Curr. Opin. Cell Biol., 9, 701-706.
87. Nagaraju, G.P. et al. (2011) Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat. Rev., 37, 559-566.
88. Murphy-Ullrich, J.E. (2001) The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J. Clin. Invest., 107, 785-790.
89. Bradshaw, A.D. et al. (1999) Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol. Biol. Cell, 10, 1569-1579.
90. Everitt, E.A. et al. (1992) Expression of SPARC is correlated with altered morphologies in transfected F9 embryonal carcinoma cells. Exp. Cell Res., 199, 134-146.
91. Said, N. et al. (2007) Normalization of the ovarian cancer microenvironment by SPARC. Mol. Cancer Res., 5, 1015-1030.
92. DiMilla, P.A. et al. (1991) Mathematical model for the effects of adhesion and mechanics on cell migration speed. Biophys. J., 60, 15-37.
93. Palecek, S.P. et al. (1997) Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature, 385, 537-540.
94. Yan, Q. et al. (1999) SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem., 47, 1495-1506.
95. Thomas, S.L. et al. (2010) PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHCRAF-ERK and AKT signaling. Neuro. Oncol., 12, 941-955.
96. Guweidhi, A. et al. (2005) Osteonectin influences growth and invasion of pancreatic cancer cells. Ann. Surg., 242, 224-234.
97. Rumpler, G. et al. (2003) Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp. Dermatol., 12, 761-771.
98. Massi, D. et al. (1999) Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum. Pathol., 30, 339-344.
99. Sosa, M.S. et al. (2007) Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics, 7, 4123-4134.
100. Killian, P.H. et al. (2012) Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis, 33, 2507-2519.
101. Schultz, C.R. et al. (2012) Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARCinduced glioma cell survival. Mol. Cancer, 11, 20.
102. Girotti, M.R. et al. (2011) SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/a2ß1 integrin axis. J. Invest. Dermatol., 131, 2438-2447.
103. Seux, M. et al. (2011) TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene, 30, 3049-3061.
104. Zhou, Y. et al. (2010) KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol. Ther., 9, 507-513.
105. Zhang, Z. et al. (2012) [Correlation of KLF4 and SPARC expression with the clinical characteristics of non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi, 15, 720-724.
106. Watkins, G. et al. (2005) Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins. Leukot. Essent. Fatty Acids, 72, 267-272.
107. Blobe, G.C. et al. (2000) Role of transforming growth factor beta in human disease. N. Engl. J. Med., 342, 1350-1358.
108. Motamed, K. et al. (2002) Inhibition of PDGF-stimulated and matrixmediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J. Cell. Biochem., 84, 759-771.
109. Bassuk, J.A. et al. (2000) Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney Int., 57, 117-128.
110. Ford, R. et al. (1993) Modulation of SPARC expression during butyrateinduced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. Exp. Cell Res., 206, 261-275.
111. Reed, M.J. et al. (1994) TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J. Cell. Physiol., 158, 169-179.
112. Shanker, Y.G. et al. (1998) Regulation of low density lipoprotein receptor mRNA levels by estradiol 17beta and chorionic gonadotropin in human placenta. Mol. Cell. Biochem., 187, 133-139.
113. Shiba, H. et al. (1998) Differential effects of various growth factors and cytokines on the syntheses of DNA, type I collagen, laminin, fibronectin, osteonectin/secreted protein, acidic and rich in cysteine (SPARC), and alkaline phosphatase by human pulp cells in culture. J. Cell. Physiol., 174, 194-205.
114. Schiemann, B.J. et al. (2003) SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol. Biol. Cell, 14, 3977-3988.
115. Shi, Q. et al. (2007) Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene, 26, 4084-4094.
116. Weaver, M.S. et al. (2008) The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J. Biol. Chem., 283, 22826-22837.
117. Tang, M.J. et al. (2007) A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J. Biol. Chem., 282, 34457-34467.
118. Lane, T.F. et al. (1994) The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J., 8, 163-173.
119. Sage, E.H. (1997) Terms of attachment: SPARC and tumorigenesis. Nat. Med., 3, 144-146.
120. Horie, K. et al. (2010) Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci., 101, 913-919.
121. Arnold, S.A. et al. (2010) Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis. Model. Mech., 3, 57-72.
122. McClung, H.M. et al. (2007) SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci. Lett., 419, 172-177.
123. Desai, N. et al. (2009) SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol., 2, 59-64.
124. Desai, N.P. et al. (2008) Improved effectiveness of nanoparticle albuminbound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer. Drugs, 19, 899-909.
125. Bhoopathi, P. et al. (2011) SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res., 71, 4908-4919.
126. Chan, J.M. et al. (2010) Secreted protein acidic and rich in cysteineinduced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53. Carcinogenesis, 31, 812-819.
127. Sailaja, G.S. et al. (2013) The secreted protein acidic and rich in cysteine (SPARC) induces endoplasmic reticulum stress leading to autophagymediated apoptosis in neuroblastoma. Int. J. Oncol., 42, 188-196.